Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 801–900 of 3,704
Bahdi, F., Shah, S. N., Dahoud, F., Farooq, M., Kozan, P. A., Kim, S. H., Sedarat, A., Shen, N., Thaker, A. M., Kolb, J. M., et al. (2025) · Clinical Obesity · doi:10.1111/cob.70001 · Cited by 19
“9,10 While these medications work at various levels, delayed gastric emptying stimulating early post-prandial fullness is an important part of their mechanism of action.”
Rodrigues, M. M., & Falcão, L. M. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133182 · Cited by 20
Brosnihan, P., Luce, M. S., Yetasook, A. K., Perez, C., Scharf, K. R., & Aly, S. (2025) · The American Surgeon™ · doi:10.1177/00031348251337145 · Cited by 17
Hunter, T. M., Cao, D., FORRESTER, T. D., Brumm, J. F., & Chao, A. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16463 · Cited by 26
Therapeutic Targeting of the GIP Receptor—Revisiting the Controversies
Campbell, J. E., & Drucker, D. J. (2025) · Diabetes · doi:10.2337/db25-0393 · Cited by 22
The Impact and Safety of GLP‐1 Agents and Breast Cancer
Parsons, K., Montalvo, M., Fischbach, N. A., Taylor, M. A., Alfaro, S., & Lustberg, M. B. (2025) · Cancer Medicine · doi:10.1002/cam4.70932 · Cited by 24
“The study found that adults who received 5, 10, and 15 mg doses of tirzepatide experienced average weight reductions of 15% (95% CI: − 15.9 to 14.2), 19.5% (95% CI: − 20.4 to − 18.5) and 20.9% (95% CI: − 21.8 to − 19.9) of initial body weight, respectively [55].”
InfluentialWulff, B. S., Chambers, A. P., Contreras, C. K. O., Kirkeby, K., Rinnov, A. R., Sustarsic, R. K., Østergaard, S., Laabs, J. E., & O'Neil, P. M. (2025) · Obesity · doi:10.1002/oby.24329 · Cited by 19
Lala, A., Beavers, C. J., Blumer, V. L., Brewer, L. C., Oliveira-Gomes, D. D., Dunbar, S. B., Every, H., Ferraro, R., Ky, B., Januzzi, J. L., et al. (2025) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2025.06.013 · Cited by 36
Lala, A., Beavers, C. J., Blumer, V. L., Brewer, L. C., Oliveira-Gomes, D. D., Dunbar, S. B., Every, H., Ferraro, R., Ky, B., Januzzi, J. L., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101069 · Cited by 27
“Similar results were seen with tirzepatide among patients with overweight or obesity and without T2DM in the Study of Tirzepatide in Participants with Obesity or Overweight (SURMOUNT-1) [83].”
Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity
Karam, L. B., Mabilleau, G., & Paccou, J. (2025) · Osteoporosis International · doi:10.1007/s00198-025-07664-1 · Cited by 30
Gut microbiome and obesity care: Bridging dietary, surgical, and pharmacological interventions
Masi, D., Watanabe, M., & Clément, K. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102573 · Cited by 25
Shifting Tides Offer New Hope For Obesity
Rosen, C. J., & Ingelfinger, J. R. (2022) · New England Journal of Medicine · doi:10.1056/nejme2206939 · Cited by 17
Vilarrasa, E., Nicolau, J., de la Cueva, P., Goday, A., Gallardo, F., Martorell, A., & Carrascosa, J. M. (2023) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2023.06.017 · Cited by 28
Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis
Karrar, H. R., Nouh, M. I., Nouh, Y. I., Nooh, M. I., Alhindi, A. S. K., Hemeq, Y. H., Aljameeli, A. M. S., Aljuaid, J. A., Alzahrani, S. J., Alsatami, A. A., et al. (2023) · Cureus · doi:10.7759/cureus.46091 · Cited by 31
“Tirzepatide was created in this situation as a new glucagon-like peptide one receptor agonist and glucose-dependent insulinotropic polypeptide receptor co-agonist that permits once-weekly subcutaneous delivery to help with blood sugar regulation and aids in weight loss [11,12].”
BackgroundPhentermine in the Modern Era of Obesity Pharmacotherapy: Does It Still Have a Role in Treatment?
Lewis, K. H., Gudzune, K. A., & Ard, J. D. (2024) · Current Obesity Reports · doi:10.1007/s13679-023-00546-9 · Cited by 25
“As a new therapeutic era is ushered in by highly efficacious incretin-based anti-obesity medications (AOMs) [1, 2], the public perception of obesity pharmacotherapy has begun to shift and demand is increasing for this treatment strategy.”
Zhang, J., Yin, B., Xi, Y., & Bai, Y. (2024) · Preventive Medicine Reports · doi:10.1016/j.pmedr.2024.102683 · Cited by 21
Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice
Song, J.-E., Ko, H., & Kim, A. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s445415 · Cited by 25
“%) had achieved a loss of ≥5%”
Pharmacological Treatment of Binge Eating Disorder and Frequent Comorbid Diseases
Himmerich, H., Bentley, J., & McElroy, S. L. (2024) · CNS Drugs · doi:10.1007/s40263-024-01111-1 · Cited by 29
“More than half of the study participants in the 10 mg and 15 mg tirzepatide groups lost 20% or more in body weight [83].”
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
Sidrak, W. R., Kalra, S., & Kalhan, A. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_442_23 · Cited by 27
“[55] In the SURMOUNT‑2 trial, [56] Tirzepatide showed weight loss benefits in IWO and T2DM.”
InfluentialKupnicka, P., Król, M., Żychowska, J., Łagowski, R., Prajwos, E., Surówka, A., & Chlubek, D. (2024) · Pharmaceuticals · doi:10.3390/ph17111470 · Cited by 26
Recent achievements and future directions of anti-obesity medications
Grandl, G., Novikoff, A., Liu, X., & Müller, T. D. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.101100 · Cited by 32
Linetzky, B., Sattar, N., Verma, S., Krumholz, H. M., Xie, C. C., Hoffmann, H. T., Zimner-Rapuch, S., Torcello-Gómez, A., & Stefanski, A. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02623 · Cited by 17
Wen, J., Syed, B., Nadora, D., How‐Volkman, C., Bernstein, E., Truong, A., Akhtar, M., Razick, A., Puglisi, J., & Frezza, E. (2025) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.70045 · Cited by 17
“There were two RCTs [9, 10] and two retrospective observational studies [5, 11].”
InfluentialAl-Najim, W., Raposo, A., BinMowyna, M. N., & le Roux, C. W. (2025) · Nutrients · doi:10.3390/nu17111934 · Cited by 16
“In the SURMOUNT-1 trial of tirzepatide, 25.7% of weight lost was attributed to lean mass [15].”
InfluentialCapturing the multifaceted function of adipose tissue macrophages
Matz, A. J., Qu, L., Karlinsey, K., Vella, A. T., & Zhou, B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148188 · Cited by 16
“Notably, glucagon-like peptide-1 (GLP-1) agonists and GLP-1 analogs are a class of medication utilized in the treatment of obesity and type 2 diabetes (68, 69).”
BackgroundRetatrutide showing promise in obesity (and type 2 diabetes)
Doggrell, S. A. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2283020 · Cited by 16
“[8].”
BackgroundMethodObesity drug shortages are symptomatic of wider malaise
Sumithran, P., Finucane, F. M., & Cohen, R. V. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01963-3 · Cited by 16
Bajaj, H. S., Welch, M., Shah, P., Luna, E., Jaouimaa, F.-Z., Liu, B., Liu, R., Chen, Y., Patel, H., & Bartee, A. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00967-0 · Cited by 23
Self-citationKaur, M., & Misra, S. (2024) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2024-0065 · Cited by 18
Jeyakumar, Y., Richardson, L., Sarma, S., Retnakaran, R. R., & Kramer, C. K. (2024) · BMJ Global Health · doi:10.1136/bmjgh-2024-017177 · Cited by 21
Bariatric surgery for treatment of morbid obesity in adults
Park, K. B., & Jun, K. (2024) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2024.219 · Cited by 19
“Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrated a 22.5% reduction in body weight in the SURMOUNT-1 trial, positioning it as one of the most effective agents with generally mild to moderate adverse events [106].”
InfluentialLiver disease trends in the Asia-Pacific region for the next 50 years
Shiina, S., Maikhuu, J., Qing, D., Batsaikhan, T., Canseco, L. M., Tobari, M., Maruyama, H., Nagamatsu, H., Alcantara‐Payawal, D., Gani, R. A., et al. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0043 · Cited by 19
Hankosky, E. R., Desai, K. R., Chinthammit, C., Grabner, M., Stockbower, G. E., He, X., Mojdami, D., Wenziger, C. M., & Gibble, T. H. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101636 · Cited by 21
Pennings, N. J., Varney, C., Hines, S., Riley, B. A., Happel, P., Patel, S., & Bays, H. E. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100172 · Cited by 26
“Tirzepatide may reduce body weight approximately 20 % at 72 weeks on a maximum dose of 15 mg injection weekly [52,94].”
The role of GIPR in food intake control
James-Okoro, P.-P., Lewis, J. E., Gribble, F. M., & Reimann, F. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1532076 · Cited by 23
“…dosing) and glycated haemoglobin levels (up to 2.6%), along with overall greater improvements in lipid pro fi les compared with 1 mg semaglutide in T2D patients, although it should be noted that a higher dose of semaglutide (2.4 mg) is currently recommended for treating obesity (4, 51 – 53, 60, 61).”
InfluentialSallam, M., Snygg, J., Ghandour, S. E., & Sallam, M. (2025) · Obesities · doi:10.3390/obesities5020026 · Cited by 21
Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies
Trapanese, V., Dagostino, A., Natale, M. R., Giofrè, F., Vatalaro, C., Melina, M., Cosentino, F., Sergi, S., Imoletti, F., Spagnuolo, R., et al. (2025) · Life · doi:10.3390/life15060843 · Cited by 25
“Until now, clinical trials have demonstrated the remarkable effectiveness of this compound, once-weekly injected, in achieving optimal glycaemic control and substantial weight reduction [44,45].”
Hepatic glycogen directly regulates gluconeogenesis through an AMPK/CRTC2 axis in mice
Zhang, B., JOHNSON, M. M., Yuan, T., Nguyen, T.-N., Okada, J., Yang, F., Xiaoli, A. M., Melikian, L. H., Xu, S., Dadpey, B., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci188363 · Cited by 20
“Our finding may also provide an explanation for the therapeutic benefits of glucagon receptor agonists for individuals with obesity and type 2 diabetes reported recently in clinical trials (72, 73).”
A novel therapeutic prospect: a dual-acting tirzepatide for Alzheimer's disease
Alshehri, G. H., Al-Kuraishy, H. M., Al-Gareeb, A. I., Fawzy, M. N., Waheed, H. J., Papadakis, M., Alexiou, A. T., & Batiha, G. E. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177979 · Cited by 20
Proglucagon-derived peptides: human physiology and therapeutic potential
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 22
The Expanding Scope of GLP-1 Receptor Agonists: Six Uses Beyond Diabetes
Sheth, K., Kim, S., Porterfield, L. R., Virani, S. S., Wadhwani, S., & Vaughan, E. M. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01319-6 · Cited by 21
“These trials resulted in a rapid evolution of the clinical landscape for GLP-1RAs in the last decade, with growing evidence supporting their role in treating obesity, cardio-vascular disease, chronic kidney disease (CKD), and other metabolic-related disorders [5–20 ].”
InfluentialEisa, N., & Barood, O. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70666 · Cited by 50
Role of systemic and epicardial adipose tissue in cardiometabolic disease
Khanna, S., Mann, G. V., Bhat, A., Lin, A., Patel, A., Nicholls, S. J., Sindone, A. P., Dey, D., Bhatt, D. L., Arnott, C. G., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01304-9 · Cited by 32
Malik, I. O., Petersen, M. C., & Klein, S. (2022) · Obesity · doi:10.1002/oby.23521 · Cited by 18
“randomized controlled trial showed that treatment with tirzepatide (15 mg/wk subcutaneous), a dual GLP-1R/glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) agonist, caused an 18% placebo-subtracted weight loss (21% total weight loss) at 72 weeks in people with obesity [6].”
BackgroundThe potential of glucagon-like peptide-1 receptor agonists in heart failure
Kreiner, F. F., Hovingh, G. K., & von Scholten, B. J. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.983961 · Cited by 17
“, 2021) or the GIP/ GLP-1 dual receptor agonist tirzepatide (Rosenstock et al., 2021; Jastreboff et al., 2022), have been shown to be associated with lower risk of incident HF and to improve established severe HF (Sundström et al.”
BackgroundTen reasons gastroenterologists and hepatologists should be treating obesity
Camilleri, M., & El-Omar, E. M. (2023) · Gut · doi:10.1136/gutjnl-2023-329639 · Cited by 19
Pharmacotherapy for obesity: recent evolution and implications for cardiovascular risk reduction
Maki, K. C., Kirkpatrick, C. F., Allison, D. B., & Gadde, K. M. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2209176 · Cited by 19
“Representative central tendencies for percent body weight changes for obesity interventions at 6 to 15 months* [11,20,41,43,50].”
BackgroundInfluentialA Women's health perspective on managing obesity
Johnson, V. R., Anekwe, C. V., Bell-Washington, T., Chhabria, S. M., Tu, L., & Stanford, F. C. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.04.007 · Cited by 19
Philosophically, is obesity really a disease?
Steele, M., & Finucane, F. M. (2023) · Obesity Reviews · doi:10.1111/obr.13590 · Cited by 23
“This new knowledge has led to better treatments, including drugs like semaglutide and tirzepatide.(26,27) These drugs, like bariatric surgery,(28) typically lead to significant weight loss and to improvements in overall metabolic health.”
Larsen, A. T., Karsdal, M. A., & Henriksen, K. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175837 · Cited by 16
Kurtzhals, P., Kreiner, F. F., & Bindra, R. S. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110881 · Cited by 22
NK cells vs. obesity: A tale of dysfunction & redemption
Barra, C. D., O'Shea, D. B., & Hogan, A. E. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109744 · Cited by 21
The pathogenesis of obesity in people living with HIV
Bailin, S. S., Koethe, J. R., & Rebeiro, P. F. (2023) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000834 · Cited by 22
Contemporary Clinical Perspectives on Targeting Remission of Type 2 Diabetes
Retnakaran, R. R., Kashyap, S. R., Gerstein, H. C., & Aroda, V. R. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad746 · Cited by 19
Powell, L. H., Daniels, B. T., Drees, B. M., Karavolos, K., Lohse, B., Masters, K. S., Nicklas, J. M., Ruder, E. H., Suzuki, S., Trabold, N., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2023.12.016 · Cited by 17
The Benefit of Healthy Lifestyle in the Era of New Medications to Treat Obesity
Grave, R. D. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s447582 · Cited by 19
“5,6 Behavioural strategies, such as daily recording of diet and activity using a diary or smartphone app, were also employed to this end in some cases.”
MethodTirzepatide-induced ketoacidosis in non-diabetic patients
Iqbal, P. M. R., Maadarani, O. S., & Bitar, Z. I. (2024) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2024_004357 · Cited by 38
“It is an approved and effective treatment for obesity in patients with and without diabetes mellitus [3] .”
BackgroundMiller, E. M., & Miller, K. (2024) · Clinical Diabetes · doi:10.2337/cd23-0077 · Cited by 18
Regulation of energy metabolism through central GIPR signaling
Liśkiewicz, A., & Müller, T. D. (2024) · Peptides · doi:10.1016/j.peptides.2024.171198 · Cited by 18
“In the SURMOUNT-1 study, mean placebo-corrected weight loss achieved by tirzepatide was 17,8% after 72 wks treatment, and with 50% of patients in the 10 mg group, and 57% in the 15 mg group, achieving weight loss > 20% (relative to 3% of patients treated with placebo) [23].”
Golubić, R., Kennet, J., Parker, V., Robertson, D. C., Luo, D., Hansen, L. B., Jermutus, L., Ambery, P., Ryaboshapkina, M., Surakala, M., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15579 · Cited by 21
Willson, C. M., Patel, L., Middleton, P., & Desai, M. M. (2024) · Cureus · doi:10.7759/cureus.58042 · Cited by 26
“Furthermore, GLP-1 has been shown to increase the secretion of somatostatin from pancreatic δ -cells [4].”
BackgroundHypogonadism and nonalcoholic fatty liver disease
Papadimitriou, K., Mousiolis, A. C., Mintziori, G., Tarenidou, C., Pοlyzos, S. A., & Goulis, D. G. (2024) · Endocrine · doi:10.1007/s12020-024-03878-1 · Cited by 19
Xie, C., Alkhouri, N., & Elfeki, M. A. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i5.731 · Cited by 23
Management of obesity in menopause
Palacios, S., Chedraui, P. A., Sánchez‐Borrego, R., Coronado, P., Simoncini, T., Schauding, K., Hillard, T., & Nappi, R. E. (2024) · Climacteric · doi:10.1080/13697137.2024.2374760 · Cited by 19
“…and tolerability of tirzepatide have been evaluated, with gastrointestinal side effects such as nausea and diarrhea being observed. its administration is subcutaneous, typically once weekly. the efficacy of tirzepatide positions it as a promising option in the management of female obesity [47].”
Khan, T. T. S., Sheikh, Z., Maleknia, S. D., Oveissi, F., Fathi, A., Abrams, T., Ong, H. X., & Traini, D. (2024) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2024.2387110 · Cited by 21
“A dual agonist, Tirzepatide, which is a combination of GLP-1 RA and glucose-dependent insulinotropic polypeptide receptor agonist (GIP RA), has also been recently approved by FDA for long-term obesity control [8,10,12].”
InfluentialJassil, F. C., Papageorgiou, M., Mackay, E., Carnemolla, A., Kingett, H., Doyle, J., Kirk, A., Lewis, N., Montagut, G., Marvasti, P., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae496 · Cited by 23
The Role of Obesity as a Cardiac Disease Risk Factor in Patients with Type 2 Diabetes
Koirala, S., Sunnaa, M., Bernier, T. D., & Oktay, A. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02129-z · Cited by 17
Weight Loss Blockbuster Development: A Role for Unimolecular Polypharmacology
Zhou, Q., Li, G., Hang, K., Li, J., Yang, D., & Wang, M. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061324-011832 · Cited by 16
A Rare Case of Tirzepatide-Induced Hepatotoxicity
Sohal, A., Casanova, L., & Kowdley, K. V. (2024) · ACG Case Reports Journal · doi:10.14309/crj.0000000000001484 · Cited by 20
McIntyre, R. S., & Kwan, A. T. H. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2430306 · Cited by 23
Mahar, M. U., Mahmud, O., Ahmed, S., Qureshi, S. A., Kakar, W. G., & Fatima, S. S. (2024) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes24008 · Cited by 31
“7 Similarly, GLP-1 has been shown to decrease gastric emptying, suppress appetite (and thus support behavioral changes to decrease body weight), and improve lipid metabolism, and it might have additional cardio and neuroprotective properties.”
InfluentialDrug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom
Knezović, E., Hefer, M., Blažanović, S., Petrović, A., Tomičić, V., Srb, N., Kirner, D., Smolić, R., & Smolić, M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47030154 · Cited by 19
“Dual GLP-1 and GIP agonists, such as tirzepatide, have shown more profound effects, including significant weight reduction in the SURMOUNT study [70].”
Glenny, E. M., Coleman, M. F., Clutton, G. T., Riesenberg, B. P., Ho, A. N., McFarlane, T. L., Kiesel, V. A., Kucinskas, A. L., Bailey, E. G., Sanchez, K. E., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.20.576484 · Cited by 18
“While tirzepatide and retatrutide, a related GLP-1/GIP/glucagon receptor triple agonist, induce weight loss comparable to bariatric surgery 7,16,17 , their anticancer benefits are unknown.”
BackgroundSpreckley, M., Ruggiero, C. F., & Brown, A. (2026) · Obesity Reviews · doi:10.1111/obr.70079 · Cited by 16
Scragg, J., Koutoukidis, D. A., Dirksen, C., Heitmann, B. L., & Jebb, S. A. (2025) · Med · doi:10.1016/j.medj.2025.100805 · Cited by 16
Xu, Y., Echouffo Tcheugui, J. B., Coresh, J., Grams, M. E., Selvin, E., Fang, M., & Shin, J. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16300 · Cited by 15
Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic
Seier, S., Stamp‐Larsen, K., Jensen, S. B. K., Torekov, S. S., & Gudbergsen, H. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70096 · Cited by 15
Pasqualotto, E., Ferreira, R. O. M., Chavez, M. P., Hohl, A., Ronsoni, M. F., Pasqualotto, T., Moraes, F. C. A. D., Hespanhol, L., Figueiredo Watanabe, J. M., Lütkemeyer, C., et al. (2024) · Metabolism Open · doi:10.1016/j.metop.2024.100321 · Cited by 15
“Recently introduced as a pharmacotherapeutic intervention for obesity, semaglutide 2.4 mg has manifested a notable placebo-adjusted weight reduction of 12.4 %, with almost one-third of participants achieving a substantial weight loss of 20 % or more [23,24].”
InfluentialTinsley, G. M., & Nadolsky, S. (2025) · SAGE Open Medical Case Reports · doi:10.1177/2050313x251388724 · Cited by 15
What is the evidence regarding the safety of new obesity pharmacotherapies
Vidal, J., Flores, L., Jiménez, A., Pané, A., & de Hollanda, A. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01488-5 · Cited by 15
“…with tirzepatide in subjects with T2D [17], as well as data from phase 3 trials evaluating the ef fi cacy of this drug for WL in PLWO with or without T2D [13 – 16], tirzepatide (administered subcutaneously at weekly doses of 5, 10, or 15 mg) has also been approved for the treatment of obesity.”
InfluentialMechanisms and treatment of obesity-related hypertension—Part 2: Treatments
Parvanova, A. I., Abbate, M., Reseghetti, E., & Ruggenenti, P. L. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf035 · Cited by 23
“Numerous RCTs have also reported that tirzepatide effectively lowers BP [159 , 162 , 164 ].”
Fabry Disease: Insights into Pathophysiology and Novel Therapeutic Strategies
Thompson, S., Roy, A., Geberhiwot, T., Gehmlich, K., & Steeds, R. P. (2025) · Biomedicines · doi:10.3390/biomedicines13030624 · Cited by 24
Siebert, S., Sattar, N. A., & Ferguson, L. D. (2025) · Joint Bone Spine · doi:10.1016/j.jbspin.2025.105904 · Cited by 21
Liu, L., Cui, J., Neidecker, M. V., & Nahata, M. C. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.31.5.441 · Cited by 33
Thin, L. W. Y., & Teh, W. L. (2025) · Biomedicines · doi:10.3390/biomedicines13051128 · Cited by 19
“…effective and longer lasting in duration, with the latest versions being liraglutide (once-daily injection), semaglutide (once-weekly injection) [49], and tirzepatide (once-weekly injection), the latter which is an agonist of the glucose-dependant insulinotropic polypeptide (GIP) receptor [51].”
Masuda, Y., Ohbayashi, K., & Iwasaki, Y. (2025) · Diabetology International · doi:10.1007/s13340-025-00819-9 · Cited by 17
Mesinovic, J., Hurst, C., Leung, G. K. W., Ryan, J. R., Daly, R. M., & Scott, D. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09968-3 · Cited by 26
“However, these interventions are also associated with substantial lean mass losses comprising of ~ 25% and ~ 39% of total weight loss for Tirzepatide and Semaglutide, respectively [130, 132].”
InfluentialTirzepatide: a novel therapeutic approach for Alzheimer’s disease
Alshehri, G. H., Al-Kuraishy, H. M., Waheed, H. J., Al-Gareeb, A. I., Faheem, S. A., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01649-z · Cited by 21
“In addition, T2D prohibits neuronal autophagy, which involves the elimination of Aβ, leading to the accumulation of Aβ clinical trial detected that once-weekly TRZ produced a dose-dependent effect in the sustained reduction of body weight of obese patients (Jastreboff et al. 2022).”
Borner, T., Pataro, A. M., Doebley, S. A., Furst, C. D., White, A. D., Gao, S. X., Chow, A., Sanchez-Navarro, M. J., Ghidewon, M. Y., Halas, J. G., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu1589 · Cited by 21
“Positive clinical results from tirzepatide (originally named LY3298176) ( 15 – 17 ), a long-acting “sequence-mixed” GIP and GLP-1 receptor agonist, led to FDA approval for T2DM and obesity treat-ment.”
GLP-1-based therapeutics for cardiorenal protection in metabolic diseases
Apperloo, E. M., Heerspink, H. J. L., van Raalte, D. H., & Muskiet, M. H. A. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf110 · Cited by 25
“1) and has achieved ≥ 20% weight loss in non-T2D [55 ].”
Ard, J. D., Lee, C. J., Gudzune, K. A., Addison, B., Lingvay, I., Cao, D., Mast, C. J., Stefański, A., Falcón, B. L., & Mojdami, D. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16554 · Cited by 28
Self-citationMari, A., Stefański, A., van Raalte, D. H., Ma, X., LaBell, E. S., Fan, L., Lee, C. J., Thomas, M. K., Bunck, M. C. M., & Ferrannini, E. (2025) · Diabetes Care · doi:10.2337/dc25-0763 · Cited by 23
Self-citationTian, Q., Song, Y., Deng, Y., & Lin, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1593134 · Cited by 26
Hankosky, E. R., Lebrec, J., Lee, C. J., Dimitriadis, G. K., Jouravskaya, I., Stefanski, A., & Garvey, W. T. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70143 · Cited by 17
“20,21 The three-year SURMOUNT-1 trial was conducted in accordance with the ethical principles of Good Clinical Practice and the Declaration of Helsinki.”
InfluentialSelf-citationHistory of glucagon-like peptide-1 receptor agonists
Darwish, R., Abu-Sharia, G., & Butler, A. E. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.108045 · Cited by 29
Chao, A. M., Gilden, A. H., & Wadden, T. A. (2026) · PLoS Medicine · doi:10.1371/journal.pmed.1004871 · Cited by 21
Lei, L., Wang, B., Zhao, L., Li, J., Yan, X., Jiang, J., Wang, L., Ren, G., Li, Y., Cheng, X., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.54152 · Cited by 24
Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures
Liu, Y., Walzer, D., Schmitz, S. H., Shukla, A. P., Ma, X., Chirko, D., Pipia, I., Sathi, S., Shukairy, U., Greenberg, M. D., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag052 · Cited by 34
Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 35
Lebwohl, M., Blauvelt, A., Kartman, C. E., Leatherwood, C., Gordon, K. B., Sattar, N. A., Puig, L., Merola, J. F., Siu, K., Wang, R., et al. (2026) · JAMA Dermatology · doi:10.1001/jamadermatol.2026.1753 · Cited by 31
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.